Back to search results
NCT05332054

Long-Term Follow-up Study

Enrolling by Invitation
Not specifiedAges 18+Observational
Caribou Biosciences, Inc.
~150 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:Caribou-sponsored investigational therapy

At a glance

Recruiting sites
0 of 31 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of targeted NSAEs
Measured over 15 Years
+12 more outcomes measured

Conditions

Lymphoma, Non-Hodgkin
Relapsed Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Lymphoma
B Cell Lymphoma
B-Cell Non-Hodgkin's Lymphoma
Hematologic Malignancy
Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Acute Myeloid Leukemia

Explore related trials

Acute Myeloid LeukemiaB-Cell Non-Hodgkin LymphomaMalignant neoplasm of lymphoid, hematopoietic and/or related tissueMultiple Myeloma

Where it's being run

31 sites across 19 states
New York3
Texas3
Arizona2
California2
Colorado2
Florida2
Georgia2
Kentucky2

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment
Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.

Exclusion

None

What this trial measures

  • Incidence of targeted NSAEs15 Years

    Incidence of targeted NSAEs

  • Frequency of targeted NSAEs15 Years

    Frequency of targeted NSAEs

  • Duration of targeted NSAEs15 Years

    Duration of targeted NSAEs

  • Outcome of targeted NSAEs15 Years

    Outcome of targeted NSAEs

  • Incidence of AESIs15 Years

    Incidence of AESIs

  • Frequency of AESIs15 Years

    Frequency of AESIs

  • Duration of AESIs15 Years

    Duration of AESIs

  • Outcome of AESIs15 Years

    Outcome of AESIs

  • Incidence of targeted SAEs15 Years

    Incidence of targeted SAEs

  • Frequency of targeted SAEs15 Years

    Frequency of targeted SAEs

  • Duration of targeted SAEs15 Years

    Duration of targeted SAEs

  • Outcome of targeted SAEs15 Years

    Outcome of targeted SAEs

  • Incidence of AEs related to IP leading to death15 Years

    Incidence of AEs related to IP leading to death